Association of FGFR2 rs2981582 polymorphism and breast cancer susceptibility: An updated systematic review and meta-analysis

The present meta-analysis aims to determine whether Fibroblast Growth Factor Receptor 2 (FGFR2) rs2981582 gene polymorphism is associated with mammary carcinoma risk in Asians and Caucasians based on case-control studies. Among women worldwide, mammary carcinoma is the most common type of cancer and the leading cause of death from cancer. Despite the overlap between early-onset and late-onset mammary carcinoma rates, mammary carcinoma incidence profiles increase exponentially until menopause and then decrease. The FGFR2 is crucial to mammary carcinoma progression. The search was conducted on several databases such as Embase, PubMed, Google Scholar, and Science Direct to find the suitable case-control studies. All statistical analyses were conducted using Review Manager 5.4 software and Metagenyo. The present study consists of 23 case-control studies (21,549 controls and 18,906 mammary carcinoma cases) to examine the association between the FGFR2 rs2981582 gene polymorphism and mammary carcinoma risk. PROSPERO (ID 348820) has been used to register the review methodology. The FGFR2 gene polymorphism rs2981582 was associated with a strong association in all genetic models. In order to estimate the publication bias, the funnel plot was used. However, there did not appear to be any significant bias. As a result, it is essential to conduct more extensive epidemiological studies are needed to confirm this finding and to gain a deeper understanding of the molecular mechanisms underlying this association.